Positive Phase II results for fungal infection drug

Merck has unveiled interim Phase II data for Cancidas, an antifungal drug for pediatric patients with candidiasis, esophageal candidiasis or invasive aspergillosis. Seventy-four percent of trial participants treated with the drug achieved complete or significant improvement in signs and symptoms related to each infection type studied. No serious adverse events were reported. Cancidas has been approved for adults but not for children under 18.

"These interim results are a preliminary indicator that Cancidas may be a therapeutic intervention for pediatric patients with invasive fungal infections," said Dr. Theoklis Zaoutis, the lead study investigator.

- see the release for more

Suggested Articles

Last month, rumors out of Bloomberg whispered that Gilead, more known for its COVID-19 work these days, was gearing up for a major stake in Arcus.

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Canadian biotech AbCellera has nabbed a meaty $105 million series B funding round as it looks to boost its antibody work and seek out new potential me